Pioneer in phage-based diagnostics

Twitter Youtube Linkedin Envelope
  • Home
  • About PBD Biotech
    • About
    • Research
    • Blog
  • Phage-based diagnostics
  • Animal Health
    • Animal Health
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Human Health
  • Contact us
  • Home
  • About PBD Biotech
    • About
    • Research
    • Blog
  • Phage-based diagnostics
  • Animal Health
    • Animal Health
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Human Health
  • Contact us

New Centre for Phage Research features Actiphage within Innovation Showcase

The UK’s first Centre for Phage Research officially launched on 16th May 2023 and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.
  • May 12, 2023
  • Corporate
Actiphage TB diagnostic releases bacterial DNA for qPCR
Actiphage TB diagnostic releases bacterial DNA for qPCR

Tuberculosis is caused by a bacterium that has evolved to evade the body’s immune system; now, its natural enemy, a phage, is being used to detect the infection at an early stage.

Catherine Rees, Professor of Microbiology at University of Nottingham, is a co-founder of PBD Biotech, developers of Actiphage. She comments: “I am delighted to be supporting the launch of the University of Leicester’s Centre for Phage Research and to be given an opportunity to highlight our phage-based technology in the KTN UK Phage Innovation Showcase. These developments emphasise the UK’s recognised strength in phage research and I look forward to the exciting new collaborations and technology developments that will arise from these important networking events.”

A quarter of the world’s population are carriers of tuberculosis but show no symptoms. It can remain hidden in the body and only progress to full disease when the immune system is weakened, perhaps by other disease or malnutrition. Tuberculosis disease is preventable but can be fatal unless treated. The challenge is how to detect the people that have active disease and treat them before they become infective – thereby breaking the cycle of infection.

Cath Rees

The bacterium, Mycobacterium tuberculosis (Mtb) has proven difficult to detect as it has a hard cell wall that prevents the release of its DNA, and it is slow to culture. Actiphage uses a phage, a virus specific to Mtb, to find live cells of Mtb in the blood.

Dr Pranab Haldar
Dr Pranab Haldar

Research at the NIHR Respiratory Biomedical Research Centre in Leicester by Clinical Senior Lecturer and Honorary Consultant Physician, Dr Pranabashis Haldar, has shown that Mtb detected in the blood using Actiphage is an indicator of active TB disease; this is a potential breakthrough in the fight to End TB.

Dr Haldar comments: “As we see with the Actiphage test, phages can enhance the scope and sensitivity of molecular diagnostics for bacterial infections by providing a mechanism to identify and release target genetic material for PCR based amplification.

“There are specific phages known to infect the vast majority of bacteria that cause infections. Phages are also versatile and may be modified to enable different approaches to the development of clinical diagnostics.”

Dr Haldar has been invited to join a panel group at the event and he thinks that phages will have multiple roles in the prevention and treatment of bacterial infections.

For more information about the Centre for Phage Research visit le.ac.uk/research/centres/phage-research.

Register for the launch event at iuk.ktn-uk.org/events/uk-phage-innovation-showcase/.

Share:

Related posts

Loading...
Laboratory Support from PBD Biotech

New qPCR kit offers rapid Mycobacterial detection

July 2, 2025
NEW - Lyophilised qPCR Kit for Mycobacterium tuberculosis Complex Detection
Laboratory Support from PBD Biotech

New qPCR kit offers rapid Mycobacterial detection

July 2, 2025
NEW - Lyophilised qPCR Kit for Mycobacterium tuberculosis Complex Detection
Actiphage TB diagnostic releases bacterial DNA for qPCR

Commercial opportunities with PBD Biotech

June 30, 2025
PBD Biotech is actively seeking commercial partnerships to exploit its patented technology.
Actiphage TB diagnostic releases bacterial DNA for qPCR

Commercial opportunities with PBD Biotech

June 30, 2025
PBD Biotech is actively seeking commercial partnerships to exploit its patented technology.
mycobacteria

Work by phage pioneers celebrated in World Antimicrobial Awareness Week

November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for tuberculosis.
mycobacteria

Work by phage pioneers celebrated in World Antimicrobial Awareness Week

November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for...
Certificate of Grant (web)

Actiphage TB patent granted in South Africa

November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements the regional West Africa patent gained earlier this year.
Certificate of Grant (web)

Actiphage TB patent granted in South Africa

November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements...
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
B4 Parkside Knowledge Gateway
Nesfield Road
Colchester
CO4 3ZL
United Kingdom

info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2025 PBD Biotech Ltd

design: out of house